Pemetrexed treatment produces better outcomes in ALK-translocated NSCLC patients

Links shared publicly online about this topic.

27
total visits

Pemetrexed treatment produces better outcomes in ALK-translocated NSCLC patients

Patients with ALK-rearranged non-small cell lung cancer (NSCLC) responded significantly better to pemetrexed than patients whose cancer did not show ALK translocation, according to research published in the September issue of the Journal of Thoracic Oncology, the official publication of the International Association for the Study of Lung Cancer.

View full resource at news-medical.net

Tags: Lung Cancer, Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer Medication, Lung, Alimta, Oncology, News